Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)

Journal of Hepatology

Volumn 65, Issue 6, 2016, Pages 1086-1093

  Waziry, Reem ^a   Grebely, Jason ^a   Amin, Janaki ^a   Alavi, Maryam ^a   Hajarizadeh, Behzad ^a   George, Jacob ^b   Matthews, Gail V ^a   Law, Matthew ^a   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Australia; Data linkage; Epidemiology; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ALCOHOL;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE NOTIFICATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; NEW SOUTH WALES; PRIORITY JOURNAL; RURAL AREA; AUSTRALIA; HEPACIVIRUS; LIVER TUMOR; RISK FACTOR;

AUSTRALIA; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; NEW SOUTH WALES; RISK FACTORS;

EID: 84995379974     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.010     Document Type: Article

References (47)

1. [1] Altekruse, S.F., McGlynn, K.A., Reichman, M.E., Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27 (2009), 1485–1491.
2. [2] Murray, C.J., Lopez, A.D., Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349 (1997), 1498–1504.
3. [3] Weinmann, A., Koch, S., Niederle, I.M., Schulze-Bergkamen, H., Konig, J., Hoppe-Lotichius, M., et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC registry. J Clin Gastroenterol 48 (2014), 279–289.
4. [4] Llovet, J.M., Burroughs, A., Bruix, J., Hepatocellular carcinoma. Lancet 362 (2003), 1907–1917.
5. [5] Beste, L.A., Leipertz, S.L., Green, P.K., Dominitz, J.A., Ross, D., Ioannou, G.N., Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in us veterans, 2001–2013. Gastroenterology 149 (2015), 1471–1482, e1475.
6. [6] Manne, V., Akhtar, E., Saab, S., Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. J Clin Gastroenterol 48 (2014), e76–e84.
7. [7] Farazi, P.A., DePinho, R.A., Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006), 674–687.
8. [8] Mittal, S., El-Serag, H.B., Epidemiology of HCC: consider the population. J Clin Gastroenterol, 47, 2013, S2.
9. [9] Walter, S.R., Thein, H.H., Gidding, H.F., Amin, J., Law, M.G., George, J., et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol 26 (2011), 1757–1764.
10. [10] Huang, Y.T., Jen, C.L., Yang, H.I., Lee, M.H., Su, J., Lu, S.N., et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 29 (2011), 3643–3650.
11. [11] Yip, B., Wantuck, J.M., Kim, L.H., Wong, R.J., Ahmed, A., Garcia, G., et al. Clinical Presentation and survival of Asian and Non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci 59 (2014), 192–200.
12. [12] Kanwal, F., Hoang, T., Kramer, J.R., Asch, S.M., Goetz, M.B., Zeringue, A., et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140 (2011), 1182–1188, e1181.
13. [13] Moorman, A.C., Xing, J., Ko, S., Rupp, L.B., Xu, F., Gordon, S.C., et al. Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention. Hepatology 61 (2014), 1479–1484.
14. [14] Kenny-Walsh, E., Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 340 (1999), 1228–1233.
15. [15] Alavi, M., Law, M.G., Grebely, J., Thein, H.H., Walter, S., Amin, J., et al. Lower life expectancy among people with an HCV notification: a population-based linkage study. J Viral Hepat 21 (2014), e10–e18.
16. [16] Amin, J., Law, M.G., Bartlett, M., Kaldor, J.M., Dore, G.J., Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 368 (2006), 938–945.
17. [17] The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2011., 2011, The Kirby Institute, UNSW Australia.
18. [18] The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2014., 2014, The Kirby Institute, UNSW Australia.
19. [19] Allard, N.L., MacLachlan, J.H., Cowie, B.C., The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment. Aust N Z J Public Health 39 (2015), 255–259.
20. [20] The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2015. Sydney NSW 2052., 2015, The Kirby Institute, UNSW Australia.
21. [21] Liver EAFTSOT. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
22. [22] Terrault, N.A., Bzowej, N.H., Chang, K.M., Hwang, J.P., Jonas, M.M., Murad, M.H., AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
23. [23] Dore, G.J., The changing therapeutic landscape for hepatitis C. Med J Aust 196 (2012), 629–632.
24. [24] Dore, G.J., Feld, J.J., Hepatitis C virus therapeutic development: in pursuit of perfectovir. Clin Infect Dis 60 (2015), 1829–1836.
25. [25] Hsiang, J., Bai, W., Raos, Z., Stableforth, W., Upton, A., Selvaratnam, S., et al. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand. Intern Med J 45 (2015), 160–169.
26. [26] Vezali, E., Aghemo, A., Colombo, M., A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 32 (2010), 2117–2138.
27. [27] Hézode, C., Fontaine, H., Dorival, C., Larrey, D., Zoulim, F., Canva, V., et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)–NCT01514890. J Hepatol 59 (2013), 434–441.
28. [28] Bruno, S., Shiffman, M.L., Roberts, S.K., Gane, E.J., Messinger, D., Hadziyannis, S.J., et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 51 (2010), 388–397.
29. [29] Hajarizadeh, B., Grebely, J., McManus, H., Estes, C., Razavi, H., Gray, R.T., et al. Chronic hepatitis C burden and treatment uptake in Australia: updated figures at the beginning of a new era. Front Drug Dev Viral Hepat Global Antivir J 11 (2015), 85–86 [Abstract].
30. [30] Sievert, W., Razavi, H., Estes, C., Thompson, A.J., Zekry, A., Roberts, S.K., et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol 29 (2014), 1–9.
31. [31] Foster, G.R., Irving, W.L., Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
32. [32] Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
33. [33] Poordad, F., Schiff, E.R., Vierling, J.M., Landis, C., Fontana, R.J., Yang, R., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
34. [34] Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
35. [35] Chiang, C.J., Yang, Y.W., Chen, J.D., You, S.L., Yang, H.I., Lee, M.H., et al. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology 61 (2015), 1154–1162.
36. [36] Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J., Bell, B.P., The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45 (2006), 529–538.
37. [37] Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 41 (2009), 1100–1104.
38. [38] Eslam, M., Hashem, A.M., Leung, R., Romero-Gomez, M., Berg, T., Dore, G.J., et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun, 6, 2015.
39. [39] Lettmeier, B., Mühlberger, N., Schwarzer, R., Sroczynski, G., Wright, D., Zeuzem, S., et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 49 (2008), 528–536.
40. [40] Volk, M.L., Tocco, R., Saini, S., Lok, A.S., Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50 (2009), 1750–1755.
41. [41] Razavi, H., Waked, I., Sarrazin, C., Myers, R., Idilman, R., Calinas, F., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21 (2014), 34–59.
42. [42] Beste, L.A., Ioannou, G.N., Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev 37 (2015), 131–143.
43. [43] Kramer, J., Davila, J., Miller, E., Richardson, P., Giordano, T., EL-SERAG, H., The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 27 (2008), 274–282.
44. [44] Davila, J.A., Henderson, L., Kramer, J.R., Kanwal, F., Richardson, P.A., Duan, Z., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus–infected veterans in the United States. Ann Intern Med 154 (2011), 85–93.
45. [45] Ioannou, G.N., Splan, M.F., Weiss, N.S., McDonald, G.B., Beretta, L., Lee, S.P., Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 5 (2007), 938–945, e934.
46. [46] El-Serag, H.B., Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35 (2002), S72–S78.
47. [47] Adams, W.L., Yuan, Z., Barboriak, J.J., Rimm, A.A., Alcohol-related hospitalizations of elderly people: prevalence and geographic variation in the United States. JAMA 270 (1993), 1222–1225.